Pioneering the next generation of non-viral gene therapy
Anjarium Biosciences has raised €51M across 1 funding round from 5 investors, most recently a Series A round in Sep 2021. Based in Schlieren, Switzerland; active in Healthtech. Data as of 6 Aug 2026.
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2021-09-16 | Series A |
| €51M |
| Abingworth,Gimv,Omega Funds,Pfizer Ventures,Surveyor Capital |
| View deal → |
